{
  "meta": {
    "title": "Hematological_Neoplasms_-_Part_2",
    "url": "https://brainandscalpel.vercel.app/hematological-neoplasms-part-2-bc4586ed.html",
    "scrapedAt": "2025-11-29T18:24:55.160Z"
  },
  "questions": [
    {
      "id": 20786,
      "choices": [
        {
          "id": 83107,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Daratumumab monotherapy </span></span></span></p>"
        },
        {
          "id": 83108,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Corticosteroids (CS) + IMiD (e.g., lenalidomide) </span></span></span></p>"
        },
        {
          "id": 83109,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CS + proteasome inhibitor (e.g., bortezomib) + daratumumab </span></span></span></p>"
        },
        {
          "id": 83110,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Autologous hematopoietic stem cell transplant (HSCT)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old patient with newly diagnosed multiple myeloma and no significant comorbidities is being evaluated for treatment. Which of the following is the most appropriate initial therapy?</span></span></p>",
      "unique_key": "Q4084995",
      "question_audio": null,
      "question_video": null,
      "map_id": 20747,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) CS + proteasome inhibitor (e.g., bortezomib) + daratumumab</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of corticosteroids (CS), an immunomodulatory drug (IMiD) like lenalidomide or pomalidomide, a proteasome inhibitor like bortezomib or carfilzomib, and daratumumab (anti-CD38 monoclonal antibody) is the standard initial therapy for transplant-eligible patients with multiple myeloma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Daratumumab monotherapy:</span></strong><span style=\"font-size:12.0pt\"> While daratumumab is a potent anti-CD38 monoclonal antibody with significant efficacy in multiple myeloma, it is not typically used as a single agent in the initial treatment of newly diagnosed patients. It is usually combined with other drugs to achieve a more robust response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Corticosteroids (CS) + IMiD (e.g., lenalidomide):</strong> This combination can be effective, but it is not the standard of care for transplant-eligible patients. Adding a proteasome inhibitor (PI) to this regimen has been shown to improve response rates and survival.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Autologous hematopoietic stem cell transplant (HSCT):</strong> HSCT is a consolidation therapy option for multiple myeloma patients after initial induction therapy. It is not the first-line treatment, but it is often considered for transplant-eligible patients who achieve a good response to induction therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The standard initial therapy for multiple myeloma involves a combination of drugs targeting different pathways to maximize efficacy.</span></span></span></p>",
      "correct_choice_id": 83109,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20731,
      "choices": [
        {
          "id": 82887,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2 </span></span></span></p>"
        },
        {
          "id": 82888,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3 </span></span></span></p>"
        },
        {
          "id": 82889,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">4 </span></span></span></p>"
        },
        {
          "id": 82890,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old male presents with stage IV CHL, an albumin of 3.5 g/dL, hemoglobin of 9 g/dL, and a WBC count of 16,000/&micro;L with 500 lymphocytes/&micro;L. According to the IPS, how many risk factors does he have?</span></span></p>",
      "unique_key": "Q5254536",
      "question_audio": null,
      "question_video": null,
      "map_id": 20692,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 4</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has the following risk factors:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Albumin &lt; 4 g/dL</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemoglobin &lt; 10.5 g/dL</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage IV disease</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphocytes &lt; 600/&micro;L</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The IPS identifies patients with a higher risk of treatment failure and helps guide therapy decisions.</span></span></span></p>",
      "correct_choice_id": 82889,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20733,
      "choices": [
        {
          "id": 82895,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(11;14) </span></span></span></p>"
        },
        {
          "id": 82896,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(14;18) </span></span></span></p>"
        },
        {
          "id": 82897,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(8;14) </span></span></span></p>"
        },
        {
          "id": 82898,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(11;18)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15-year-old male presents with a rapidly enlarging jaw mass and systemic B symptoms. Biopsy reveals medium-sized lymphoid cells with a starry sky pattern. Which of the following cytogenetic abnormalities is most likely associated with this lymphoma? </span></span></p>",
      "unique_key": "Q2121382",
      "question_audio": null,
      "question_video": null,
      "map_id": 20694,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) t(8;14)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The t(8;14) translocation is the hallmark of Burkitt lymphoma. It results in the overexpression of the MYC oncogene, leading to aggressive proliferation of B cells. The other translocations are associated with different lymphomas (A &amp; D: Mantle Cell Lymphoma, B: Follicular Lymphoma).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>A. t(11;14):</strong> This translocation is characteristic of Mantle Cell Lymphoma. It involves the cyclin D1 gene and leads to increased cell cycle progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. t(14;18):</strong> This translocation is associated with Follicular Lymphoma. It involves the BCL2 gene, which inhibits apoptosis and promotes cell survival.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. t(11;18):</strong> This translocation is also associated with Mantle Cell Lymphoma, like option A.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Burkitt lymphoma is a highly aggressive B-cell lymphoma characterized by a specific translocation, t(8;14).</span></span></span></p>",
      "correct_choice_id": 82897,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20736,
      "choices": [
        {
          "id": 82907,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epstein-Barr virus (EBV) </span></span></span></p>"
        },
        {
          "id": 82908,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Human Immunodeficiency Virus (HIV) </span></span></span></p>"
        },
        {
          "id": 82909,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hepatitis C virus (HCV) </span></span></span></p>"
        },
        {
          "id": 82910,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Helicobacter pylori (H. pylori)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old female presents with abdominal pain and a palpable mass. Biopsy reveals Burkitt&#39;s lymphoma. Which of the following infectious agents is most likely associated with this case? </span></span></p>",
      "unique_key": "Q3191136",
      "question_audio": null,
      "question_video": null,
      "map_id": 20697,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Epstein-Barr virus (EBV)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">EBV is strongly associated with Burkitt&#39;s lymphoma, particularly in endemic regions. The other infectious agents are not directly linked to Burkitt&#39;s lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Human Immunodeficiency Virus (HIV):</strong> While HIV infection increases the risk of various lymphomas, including Burkitt&#39;s lymphoma, it is not the most common infectious agent directly associated with Burkitt&#39;s lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Hepatitis C virus (HCV):</strong> HCV is primarily associated with liver disease and certain types of lymphoma, but not Burkitt&#39;s lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Helicobacter pylori (H. pylori):</strong> H. pylori is a bacterium that infects the stomach and is associated with gastric cancer and lymphoma of the stomach (MALT lymphoma), but not Burkitt&#39;s lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">EBV plays a significant role in the pathogenesis of Burkitt&#39;s lymphoma.</span></span></span></p>",
      "correct_choice_id": 82907,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20737,
      "choices": [
        {
          "id": 82911,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(14;18) with MYC overexpression </span></span></span></p>"
        },
        {
          "id": 82912,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MYC translocation with BCL2 or BCL6 rearrangement </span></span></span></p>"
        },
        {
          "id": 82913,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BCL2 translocation with BCL6 rearrangement </span></span></span></p>"
        },
        {
          "id": 82914,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Trisomy 12 with BCL6 rearrangement</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which genetic abnormality defines double-hit lymphoma (DHL)?</span></span></p>",
      "unique_key": "Q9752859",
      "question_audio": null,
      "question_video": null,
      "map_id": 20698,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) MYC translocation with BCL2 or BCL6 rearrangement</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DHL is characterized by a combination of MYC translocation (usually t(8;14)) and a rearrangement of either BCL2 (t(14;18)) or BCL6. This results in the overexpression of multiple oncogenes, leading to aggressive lymphoma behavior.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. t(14;18) with MYC overexpression:</strong> While t(14;18) is associated with BCL2 overexpression and is seen in follicular lymphoma, it alone does not define DHL. DHL requires the additional presence of a MYC translocation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. BCL2 translocation with BCL6 rearrangement:</strong> This combination of rearrangements is not characteristic of DHL. DHL specifically requires a MYC translocation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Trisomy 12 with BCL6 rearrangement:</strong> Trisomy 12 is associated with chronic lymphocytic leukemia (CLL), and while BCL6 rearrangement can occur in various lymphomas, this combination does not define DHL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combined dysregulation of MYC and BCL2/BCL6 is the defining feature of DHL.</span></span></span></p>",
      "correct_choice_id": 82912,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20745,
      "choices": [
        {
          "id": 82943,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(8;14) </span></span></span></p>"
        },
        {
          "id": 82944,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(11;14) </span></span></span></p>"
        },
        {
          "id": 82945,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(14;18) </span></span></span></p>"
        },
        {
          "id": 82946,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(15;17)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old woman presents with painless, slowly enlarging lymph nodes in her neck and axillae. Lymph node biopsy reveals small, cleaved lymphocytes with a follicular pattern. Which of the following genetic abnormalities is most commonly associated with this type of lymphoma?</span></span></p>",
      "unique_key": "Q1382868",
      "question_audio": null,
      "question_video": null,
      "map_id": 20706,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) t(14;18)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The t(14;18) translocation is the hallmark of follicular lymphoma (FL). It results in overexpression of the BCL2 gene, which inhibits apoptosis and promotes cell survival.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. t(8;14):</strong> This translocation is characteristic of Burkitt lymphoma. It leads to overexpression of the MYC oncogene, promoting cell growth and proliferation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. t(11;14):</strong> This translocation is associated with mantle cell lymphoma. It leads to overexpression of cyclin D1, which regulates the cell cycle.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. t(15;17):</strong> This translocation is associated with acute promyelocytic leukemia (APL). It leads to the fusion of the PML and RARA genes, disrupting normal cell differentiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(14;18) is a diagnostic feature of FL and contributes to its indolent nature.</span></span></span></p>",
      "correct_choice_id": 82945,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20746,
      "choices": [
        {
          "id": 82947,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) </span></span></span></p>"
        },
        {
          "id": 82948,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisone) </span></span></span></p>"
        },
        {
          "id": 82949,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bendamustine-rituximab (BR) </span></span></span></p>"
        },
        {
          "id": 82950,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following chemotherapy regimens is NOT typically used as a first-line treatment for symptomatic follicular lymphoma (FL)?</span></span></p>",
      "unique_key": "Q5592630",
      "question_audio": null,
      "question_video": null,
      "map_id": 20707,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HyperCVAD is a more intensive regimen typically used for aggressive lymphomas. R-CHOP, R-CVP, and BR are more common first-line options for FL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>A. R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone):</strong> This is a widely used and effective first-line treatment for FL. It combines the monoclonal antibody rituximab with a standard chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>B. R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisone):</strong> This is another commonly used first-line regimen for FL, particularly in older or less fit patients. It is similar to R-CHOP but uses vincristine instead of doxorubicin, which is associated with less cardiotoxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Bendamustine-rituximab (BR):</strong> This is a well-tolerated and effective regimen that has gained popularity as a first-line treatment for FL, especially in patients who may not tolerate the anthracycline component of R-CHOP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">FL is typically treated with less intensive chemotherapy regimens compared to aggressive lymphomas.</span></span></span></p>",
      "correct_choice_id": 82950,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20748,
      "choices": [
        {
          "id": 82955,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CD19 </span></span></span></p>"
        },
        {
          "id": 82956,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CD20 </span></span></span></p>"
        },
        {
          "id": 82957,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CD103 </span></span></span></p>"
        },
        {
          "id": 82958,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CD30</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old male presents with fatigue, splenomegaly, and pancytopenia. Peripheral blood smear shows &quot;hairy cells&quot; with cytoplasmic projections. Which of the following markers is most specific for the diagnosis of hairy cell leukemia (HCL)?</span></span></span></p>",
      "unique_key": "Q5077175",
      "question_audio": null,
      "question_video": null,
      "map_id": 20708,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) CD103</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD103 is a highly specific marker for hairy cell leukemia. While CD19 and CD20 are B-cell markers expressed in HCL, they are not specific. CD30 is associated with Hodgkin lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CD19:</span></strong><span style=\"font-size:12.0pt\"> This is a B-cell marker that is expressed in HCL, but it is not specific to HCL. It is also found on other B-cell malignancies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CD20:</span></strong><span style=\"font-size:12.0pt\"> Similar to CD19, this is a B-cell marker present in HCL but not specific to it.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CD30:</span></strong><span style=\"font-size:12.0pt\"> This marker is primarily associated with classical Hodgkin lymphoma and anaplastic large cell lymphoma. It is not expressed in HCL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD103 is a key diagnostic marker for hairy cell leukemia</span></span></span></p>",
      "correct_choice_id": 82957,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20756,
      "choices": [
        {
          "id": 82987,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute myeloid leukemia (AML) </span></span></span></p>"
        },
        {
          "id": 82988,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mantle cell lymphoma (MCL) </span></span></span></p>"
        },
        {
          "id": 82989,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) </span></span></span></p>"
        },
        {
          "id": 82990,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hodgkin lymphoma (HL)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man presents with fatigue and mild lymphadenopathy. Blood tests reveal lymphocytosis with smudge cells on peripheral smear. Flow cytometry shows CD5 and CD23 positivity. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q7402131",
      "question_audio": null,
      "question_video": null,
      "map_id": 20717,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of lymphocytosis with smudge cells and CD5/CD23 positivity is characteristic of CLL/SLL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute myeloid leukemia (AML):</span></strong><span style=\"font-size:12.0pt\"> AML is characterized by the proliferation of immature myeloid cells in the bone marrow and blood. It does not typically present with smudge cells or CD5/CD23 positivity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Mantle cell lymphoma (MCL):</strong> MCL is a type of B-cell lymphoma with a characteristic t(11;14) translocation. While it can present with lymphocytosis, it typically lacks smudge cells and does not express CD23.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hodgkin lymphoma (HL):</span></strong><span style=\"font-size:12.0pt\"> HL is characterized by the presence of Reed-Sternberg cells, which are large, atypical cells not seen in CLL/SLL. HL typically does not present with smudge cells or a predominantly lymphocytic infiltrate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CLL/SLL is a B-cell neoplasm characterized by the accumulation of small, mature lymphocytes with specific immunophenotypic markers.</span></span></span></p>",
      "correct_choice_id": 82989,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20757,
      "choices": [
        {
          "id": 82991,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumor lysis syndrome </span></span></span></p>"
        },
        {
          "id": 82992,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial fibrillation </span></span></span></p>"
        },
        {
          "id": 82993,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diarrhea </span></span></span></p>"
        },
        {
          "id": 82994,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripheral neuropathy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a potential adverse effect of venetoclax, a BCL2 inhibitor used in CLL/SLL treatment?</span></span></p>",
      "unique_key": "Q6463632",
      "question_audio": null,
      "question_video": null,
      "map_id": 20718,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Tumor lysis syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumor lysis syndrome (TLS) is a serious complication of rapid tumor cell breakdown and can occur with venetoclax therapy. The other options are not typical adverse effects of venetoclax.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Atrial fibrillation:</strong> While cardiac arrhythmias can be a side effect of some cancer therapies, atrial fibrillation is not a common side effect specifically associated with venetoclax.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Diarrhea:</strong> Diarrhea is a common side effect of many chemotherapies but is not a characteristic side effect of venetoclax.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Peripheral neuropathy:</strong> Peripheral neuropathy (damage to peripheral nerves causing numbness, tingling, or pain) can be a side effect of certain chemotherapy agents, but it is not typically associated with venetoclax.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monitoring for and preventing TLS is crucial when initiating venetoclax therapy in CLL/SLL.</span></span></span></p>",
      "correct_choice_id": 82991,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20758,
      "choices": [
        {
          "id": 82995,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Del(13q) </span></span></span></p>"
        },
        {
          "id": 82996,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Del(17p) </span></span></span></p>"
        },
        {
          "id": 82997,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutated IgVH genes </span></span></span></p>"
        },
        {
          "id": 82998,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Trisomy 12</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following genetic abnormalities is associated with a poor prognosis in CLL/SLL?</span></span></p>",
      "unique_key": "Q9528927",
      "question_audio": null,
      "question_video": null,
      "map_id": 20719,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Del(17p)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Deletion of the short arm of chromosome 17 (del(17p)) leads to loss of the TP53 tumor suppressor gene, resulting in resistance to chemotherapy and a poorer prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Del(13q):</strong> This is the most common genetic abnormality in CLL/SLL and is associated with a favorable prognosis. It typically involves deletion of the microRNA genes miR-15a and miR-16-1, which regulate B-cell survival.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Mutated IgVH genes:</strong> CLL/SLL cases with mutated IgVH genes generally have a more indolent course and better prognosis compared to those with unmutated IgVH genes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Trisomy 12:</strong> This is an intermediate-risk genetic abnormality in CLL/SLL, with a prognosis between that of del(13q) and del(17p). It can be associated with atypical morphology and increased proliferative activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">del(17p) is a high-risk genetic abnormality in CLL/SLL.</span></span></span></p>",
      "correct_choice_id": 82996,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20760,
      "choices": [
        {
          "id": 83003,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lower risk of infection </span></span></span></p>"
        },
        {
          "id": 83004,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Improved tolerability </span></span></span></p>"
        },
        {
          "id": 83005,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Higher response rates in certain patient subgroups </span></span></span></p>"
        },
        {
          "id": 83006,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a potential advantage of targeted therapies like BTK inhibitors or BCL2 inhibitors over traditional chemotherapy in CLL/SLL treatment?</span></span></p>",
      "unique_key": "Q3213549",
      "question_audio": null,
      "question_video": null,
      "map_id": 20720,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) All of the above</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Targeted therapies like BTK inhibitors (e.g., ibrutinib) and BCL2 inhibitors (e.g., venetoclax) offer several advantages over traditional chemotherapy, including a lower risk of infection, improved tolerability, and higher response rates in certain patient populations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Targeted therapies have revolutionized the treatment landscape for CLL/SLL, offering improved outcomes and reduced toxicity compared to traditional chemotherapy.</span></span></span></p>",
      "correct_choice_id": 83006,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20768,
      "choices": [
        {
          "id": 83035,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epstein-Barr virus (EBV) </span></span></span></p>"
        },
        {
          "id": 83036,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Human T-lymphotropic virus type 1 (HTLV-1) </span></span></span></p>"
        },
        {
          "id": 83037,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Human immunodeficiency virus (HIV) </span></span></span></p>"
        },
        {
          "id": 83038,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytomegalovirus (CMV)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man from Japan presents with hypercalcemia, lytic bone lesions, and skin rash. Peripheral blood smear reveals atypical lymphocytes with &quot;cloverleaf&quot; nuclei. Which of the following viruses is most likely associated with this clinical presentation?</span></span></p>",
      "unique_key": "Q1968176",
      "question_audio": null,
      "question_video": null,
      "map_id": 20729,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Human T-lymphotropic virus type 1 (HTLV-1)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HTLV-1 infection is strongly associated with the development of adult T-cell leukemia/lymphoma (ATLL). The presence of hypercalcemia, lytic bone lesions, skin rash, and atypical lymphocytes with &quot;cloverleaf&quot; nuclei are classic findings in ATLL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Epstein-Barr virus (EBV):</strong> EBV is associated with other lymphoid malignancies, such as Burkitt lymphoma and Hodgkin lymphoma, but not typically with ATLL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Human immunodeficiency virus (HIV):</strong> While HIV increases the risk of various malignancies, including lymphomas, it is not the primary cause of ATLL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Cytomegalovirus (CMV):</strong> CMV is a common virus that usually causes mild or asymptomatic infections. It is not linked to the development of ATLL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HTLV-1 infection is a crucial risk factor for ATLL, particularly in endemic regions like Japan and the Caribbean.</span></span></span></p>",
      "correct_choice_id": 83036,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20770,
      "choices": [
        {
          "id": 83043,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hodgkin lymphoma (HL) </span></span></span></p>"
        },
        {
          "id": 83044,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diffuse large B-cell lymphoma (DLBCL) </span></span></span></p>"
        },
        {
          "id": 83045,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anaplastic large cell lymphoma (ALCL) </span></span></span></p>"
        },
        {
          "id": 83046,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman with a history of breast implants presents with a rapidly enlarging axillary lymph node. Excisional biopsy reveals large atypical cells with horseshoe-shaped nuclei and abundant cytoplasm. Immunohistochemical staining shows strong expression of CD30. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q5292730",
      "question_audio": null,
      "question_video": null,
      "map_id": 20731,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Anaplastic large cell lymphoma (ALCL)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation (breast implants, rapidly enlarging lymph node), morphology (large atypical cells, horseshoe-shaped nuclei), and CD30 expression are characteristic of ALCL. While CD30 is also expressed in HL, the morphology of RS cells is different.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Hodgkin lymphoma (HL):</strong> While HL can express CD30, it lacks the characteristic hallmark cells with horseshoe-shaped nuclei seen in ALCL. RS cells are usually larger and have a bilobed or multi-lobed nucleus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Diffuse large B-cell lymphoma (DLBCL):</strong> DLBCL is a B-cell lymphoma and would not express CD30. The cells in DLBCL are also not typically described as having horseshoe-shaped nuclei.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS):</strong> PTCL-NOS is a heterogeneous group of T-cell lymphomas. While it can share some features with ALCL, it does not have the specific hallmark cells or the same association with breast implants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ALCL is a T-cell lymphoma characterized by large atypical cells, CD30 expression, and potential association with breast implants.</span></span></span></p>",
      "correct_choice_id": 83045,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20781,
      "choices": [
        {
          "id": 83087,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glomerulonephritis </span></span></span></p>"
        },
        {
          "id": 83088,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tubulointerstitial nephritis </span></span></span></p>"
        },
        {
          "id": 83089,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Light chain cast nephropathy </span></span></span></p>"
        },
        {
          "id": 83090,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obstructive uropathy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man with a history of monoclonal gammopathy of undetermined significance (MGUS) presents with new-onset renal insufficiency. Which of the following is the most likely mechanism underlying his renal dysfunction?</span></span></p>",
      "unique_key": "Q5873940",
      "question_audio": null,
      "question_video": null,
      "map_id": 20742,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Light chain cast nephropathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In multiple myeloma, light chains produced by the clonal plasma cells can precipitate in the renal tubules, leading to light chain cast nephropathy and renal insufficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Glomerulonephritis:</strong> Glomerulonephritis is an inflammation of the glomeruli, the tiny filters in the kidneys. While it can cause renal insufficiency, it&#39;s not the most common mechanism in patients with MM or MGUS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Tubulointerstitial nephritis:</strong> This condition involves inflammation of the tubules and the surrounding tissue in the kidneys. It can be caused by medications or infections but is less likely in the context of MGUS progressing to MM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Obstructive uropathy:</strong> This refers to a blockage of the urinary tract, which can lead to kidney damage. While it&#39;s possible, it&#39;s less likely to be the primary cause of renal insufficiency in a patient with MM or MGUS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The progression of MGUS to multiple myeloma often leads to the production of excess light chains, which can cause kidney damage through light chain cast nephropathy. It&#39;s a crucial consideration in the management of these patients.</span></span></span></p>",
      "correct_choice_id": 83089,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20783,
      "choices": [
        {
          "id": 83095,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&gt;60% clonal bone marrow plasma cells </span></span></span></p>"
        },
        {
          "id": 83096,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Involved SFLC &ge;100 mg/L </span></span></span></p>"
        },
        {
          "id": 83097,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&ge;2 focal lesions (&gt;5mm) on whole-body MRI </span></span></span></p>"
        },
        {
          "id": 83098,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum creatinine &gt;2 mg/dL</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is NOT a component of the SLIM criteria?</span></span></span></p>",
      "unique_key": "Q2712443",
      "question_audio": null,
      "question_video": null,
      "map_id": 20744,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Serum creatinine &gt;2 mg/dL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated serum creatinine is part of the CRAB criteria, indicating renal impairment. SLIM criteria do not include renal function assessment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The SLIM criteria focus on biomarkers indicating clonal plasma cell expansion and disease burden, while the CRAB criteria assess end-organ damage.</span></span></span></p>",
      "correct_choice_id": 83098,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20784,
      "choices": [
        {
          "id": 83099,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">15% </span></span></span></p>"
        },
        {
          "id": 83100,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">65% </span></span></span></p>"
        },
        {
          "id": 83101,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">72% </span></span></span></p>"
        },
        {
          "id": 83102,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following bone marrow plasma cell (BMPC) percentages would NOT meet the criteria for myeloma-defining events (MDE)?</span></span></p>",
      "unique_key": "Q2775794",
      "question_audio": null,
      "question_video": null,
      "map_id": 20745,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) 15%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MDE require either &ge;60% clonal BMPCs (SLIM criteria) or a biopsy-proven plasmacytoma (regardless of BMPC percentage).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MDEs can be identified by a significant clonal plasma cell burden in the bone marrow or the presence of a plasmacytoma.</span></span></span></p>",
      "correct_choice_id": 83099,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20785,
      "choices": [
        {
          "id": 83103,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monoclonal gammopathy of undetermined significance (MGUS) </span></span></span></p>"
        },
        {
          "id": 83104,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoldering multiple myeloma (SMM) </span></span></span></p>"
        },
        {
          "id": 83105,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple myeloma (MM) </span></span></span></p>"
        },
        {
          "id": 83106,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Waldenstr&ouml;m macroglobulinemia (WM)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 62-year-old male presents with a 3-month history of worsening fatigue, back pain, and unintentional weight loss. On examination, he is pale and has point tenderness over the lumbar spine. Laboratory findings reveal anemia, hypercalcemia, and elevated creatinine. A skeletal survey shows multiple lytic lesions in the spine and pelvis. Serum electrophoresis was done and the image is shown below. Which of the following is the most likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/02/screenshot-2024-08-02-104412.png\" style=\"height:147px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q7530673",
      "question_audio": null,
      "question_video": null,
      "map_id": 20746,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Multiple myeloma (MM)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation with fatigue, bone pain, weight loss, anemia, hypercalcemia, renal insufficiency (elevated creatinine), and lytic bone lesions strongly suggests multiple myeloma. These findings fulfill the CRAB criteria (hypercalcemia, Renal insufficiency, Anemia, Bone lesions) which are characteristic of MM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Monoclonal gammopathy of undetermined significance (MGUS):</strong> MGUS is a benign condition where a small amount of monoclonal protein (M-protein) is present in the blood, but there are no symptoms or signs of end-organ damage (CRAB criteria). The patient in this scenario clearly has CRAB criteria, ruling out MGUS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Smoldering multiple myeloma (SMM):</strong> SMM is a precursor to multiple myeloma and is characterized by a higher level of M-protein or bone marrow plasma cells than MGUS, but still no CRAB criteria. This patient&#39;s presentation with anemia, hypercalcemia, and renal insufficiency indicates organ damage, making SMM less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Waldenstr&ouml;m macroglobulinemia (WM):</strong> WM is a type of lymphoma where malignant B cells produce excessive IgM antibodies. While it can present with some similar features to multiple myeloma (like fatigue and anemia), it typically doesn&#39;t cause bone pain, hypercalcemia, or lytic bone lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple myeloma is a plasma cell malignancy that can present with various symptoms, including bone pain, anemia, renal insufficiency, and hypercalcemia. The presence of CRAB criteria, along with lytic bone lesions and monoclonal protein in the serum or urine, are key diagnostic features.</span></span></span></p>",
      "correct_choice_id": 83105,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20727,
      "choices": [
        {
          "id": 82871,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Classical Hodgkin Lymphoma (CHL) </span></span></span></p>"
        },
        {
          "id": 82872,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) </span></span></span></p>"
        },
        {
          "id": 82873,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diffuse large B-cell lymphoma (DLBCL) </span></span></span></p>"
        },
        {
          "id": 82874,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Follicular lymphoma (FL)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman presents with painless cervical lymphadenopathy and pruritus. Excisional biopsy of a lymph node reveals Reed-Sternberg (RS) cells positive for CD15 and CD30. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q4392002",
      "question_audio": null,
      "question_video": null,
      "map_id": 20688,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Classical Hodgkin Lymphoma (CHL)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of classical Reed-Sternberg cells positive for CD15 and CD30 is pathognomonic for CHL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)</span></strong><span style=\"font-size:12.0pt\">: This subtype is characterized by &quot;popcorn&quot; cells, which are negative for CD15 and CD30.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Diffuse large B-cell lymphoma (DLBCL)&nbsp;</span></strong><span style=\"font-size:12.0pt\">and <strong>Option D. Follicular lymphoma (FL)</strong>: These are non-Hodgkin lymphomas with different histopathological features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CHL is diagnosed based on the presence of classic RS cells positive for CD15 and CD30.</span></span></span></p>",
      "correct_choice_id": 82871,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20729,
      "choices": [
        {
          "id": 82879,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CD15 </span></span></span></p>"
        },
        {
          "id": 82880,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CD20 </span></span></span></p>"
        },
        {
          "id": 82881,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CD30 </span></span></span></p>"
        },
        {
          "id": 82882,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CD45</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following markers is typically positive in NLPHL but negative in CHL?</span></span></span></p>",
      "unique_key": "Q5818211",
      "question_audio": null,
      "question_video": null,
      "map_id": 20690,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) CD20</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&quot;Popcorn&quot; cells in NLPHL express CD20, while classic RS cells in cHL are negative for CD20.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>CD15:</strong> This marker is often positive in CHL, particularly in the Reed-Sternberg cells. It may be positive in NLPHL but is not a defining characteristic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>CD30:</strong> This marker is typically positive in CHL, especially in the Reed-Sternberg cells. It is usually negative in NLPHL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>CD45:</strong> This marker is a general leukocyte marker and is expressed in both CHL and NLPHL, but it is not helpful in differentiating between the two.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD20 expression can help differentiate between CHL and NLPHL.</span></span></span></p>",
      "correct_choice_id": 82880,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20738,
      "choices": [
        {
          "id": 82915,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) </span></span></span></p>"
        },
        {
          "id": 82916,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">R-EPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) </span></span></span></p>"
        },
        {
          "id": 82917,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine) </span></span></span></p>"
        },
        {
          "id": 82918,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Radiotherapy alone</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old male presents with a rapidly enlarging cervical lymph node and complains of fatigue, night sweats, and unintentional weight loss. A lymph node biopsy confirms the diagnosis of diffuse large B-cell lymphoma (DLBCL). Which of the following treatment regimens is the most appropriate initial therapy for this patient?</span></span></p>",
      "unique_key": "Q5440438",
      "question_audio": null,
      "question_video": null,
      "map_id": 20699,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">R-CHOP:</span></strong><span style=\"font-size:12.0pt\"> This is the standard first-line treatment for most patients with DLBCL, including the elderly. It combines the monoclonal antibody rituximab with a multi-agent chemotherapy regimen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>R-EPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin):</strong> This is a more intensive regimen typically reserved for younger patients with high-risk disease or certain subtypes of DLBCL. It may not be suitable <strong>Option</strong> for older patients due to increased toxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine):</span></strong><span style=\"font-size:12.0pt\"> This is another intensive regimen often used in specific subtypes of aggressive lymphoma or for relapsed/refractory disease. It is not the standard first-line treatment for DLBCL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Radiotherapy alone:</strong> While radiotherapy may be used in certain situations (e.g., localized disease), it is not sufficient as the sole treatment for most cases of DLBCL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">R-CHOP is the standard first-line treatment for most newly diagnosed patients with DLBCL, including the elderly.</span></span></span></p>",
      "correct_choice_id": 82915,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20739,
      "choices": [
        {
          "id": 82919,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(14;18) </span></span></span></p>"
        },
        {
          "id": 82920,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(8;14) </span></span></span></p>"
        },
        {
          "id": 82921,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(11;14) </span></span></span></p>"
        },
        {
          "id": 82922,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(15;17)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old male presents with abdominal discomfort, fatigue, and weight loss. Endoscopy reveals multiple gastric ulcers. Biopsy shows small to medium-sized lymphoid cells with CD5 expression but lacking CD23. Which of the following cytogenetic abnormalities is most characteristic of this lymphoma?</span></span></span></p>",
      "unique_key": "Q4058707",
      "question_audio": null,
      "question_video": null,
      "map_id": 20700,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) t(11;14)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(11;14) is the hallmark translocation of mantle cell lymphoma (MCL). It leads to overexpression of cyclin D1 (CCND1), driving cell cycle progression and promoting tumorigenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. t(14;18):</span></strong><span style=\"font-size:12.0pt\"> This translocation is characteristic of follicular lymphoma, not mantle cell lymphoma. It involves the BCL2 gene, which inhibits apoptosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>B. t(8;14):</strong> This translocation is the hallmark of Burkitt lymphoma. It leads to overexpression of the MYC oncogene, which promotes cell growth and proliferation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>D. t(15;17):</strong> This translocation is associated with acute promyelocytic leukemia (APL), a type of acute myeloid leukemia. It involves the PML and RARA genes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(11;14) is a diagnostic feature of MCL and is associated with cyclin D1 overexpression.</span></span></span></p>",
      "correct_choice_id": 82921,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20740,
      "choices": [
        {
          "id": 82923,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) </span></span></span></p>"
        },
        {
          "id": 82924,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bendamustine-rituximab (BR) </span></span></span></p>"
        },
        {
          "id": 82925,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine) </span></span></span></p>"
        },
        {
          "id": 82926,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a standard treatment option for mantle cell lymphoma (MCL)?</span></span></p>",
      "unique_key": "Q8088772",
      "question_audio": null,
      "question_video": null,
      "map_id": 20701,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ABVD is a standard regimen for Hodgkin lymphoma but not typically used for MCL. R-CHOP, BR, and HyperCVAD are among the treatment options for MCL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treatment for MCL involves different regimens than those used for Hodgkin lymphoma.</span></span></span></p>",
      "correct_choice_id": 82926,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20741,
      "choices": [
        {
          "id": 82927,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(8;14) </span></span></span></p>"
        },
        {
          "id": 82928,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(11;18) </span></span></span></p>"
        },
        {
          "id": 82929,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(14;18) </span></span></span></p>"
        },
        {
          "id": 82930,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(11;14)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following genetic abnormalities is most frequently associated with extranodal marginal zone lymphoma (ENMZL) of mucosa-associated lymphoid tissue (MALT)?</span></span></p>",
      "unique_key": "Q4408401",
      "question_audio": null,
      "question_video": null,
      "map_id": 20702,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) t(11;18)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The t(11;18) translocation is the most common genetic abnormality in gastric MALT lymphoma, a subtype of ENMZL. It results in the fusion of the API2 and MALT1 genes, leading to activation of NF-KB signaling and promoting lymphomagenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>A. t(8;14):</strong> This translocation is the hallmark of Burkitt lymphoma, a highly aggressive B-cell lymphoma. It leads to the overexpression of the MYC oncogene.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. t(14;18):</span></strong><span style=\"font-size:12.0pt\"> This translocation is characteristic of follicular lymphoma, another type of B-cell lymphoma. It involves the BCL2 gene, which inhibits apoptosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. t(11;14):</span></strong><span style=\"font-size:12.0pt\"> This translocation is the hallmark of mantle cell lymphoma, a type of B-cell lymphoma. It leads to overexpression of cyclin D1, promoting cell cycle progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The t(11;18) translocation is a characteristic feature of MALT lymphoma and can guide treatment decisions, as cases with this translocation may not respond to H. pylori eradication alone.</span></span></span></p>",
      "correct_choice_id": 82928,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20743,
      "choices": [
        {
          "id": 82935,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Epstein-Barr Virus (EBV) </span></span></span></p>"
        },
        {
          "id": 82936,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Helicobacter pylori </span></span></span></p>"
        },
        {
          "id": 82937,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Chlamydia psittaci </span></span></span></p>"
        },
        {
          "id": 82938,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Borrelia burgdorferi</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following infectious agents is most commonly associated with gastric MALT lymphoma?</span></span></p>",
      "unique_key": "Q5034638",
      "question_audio": null,
      "question_video": null,
      "map_id": 20704,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Helicobacter pylori</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Helicobacter pylori infection is strongly associated with gastric MALT lymphoma. Eradication of H. pylori can often lead to remission of the lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Epstein-Barr Virus (EBV):</strong> EBV is associated with several types of lymphomas, including Burkitt lymphoma and Hodgkin lymphoma, but not typically with gastric MALT lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chlamydia psittaci:</span></strong><span style=\"font-size:12.0pt\"> This bacterium is associated with psittacosis (parrot fever) and can sometimes cause conjunctivitis. It is not linked to the development of gastric MALT lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Borrelia burgdorferi:</span></strong><span style=\"font-size:12.0pt\"> This bacterium is the causative agent of Lyme disease and is sometimes associated with cutaneous (skin) MALT lymphoma, but not gastric MALT lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">H. pylori infection is a significant risk factor for developing gastric MALT lymphoma.</span></span></span></p>",
      "correct_choice_id": 82936,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20749,
      "choices": [
        {
          "id": 82959,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive tartrate-resistant acid phosphatase (TRAP) stain </span></span></span></p>"
        },
        {
          "id": 82960,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive myeloperoxidase (MPO) stain </span></span></span></p>"
        },
        {
          "id": 82961,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased serum uric acid levels </span></span></span></p>"
        },
        {
          "id": 82962,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BCR-ABL1 fusion gene</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following laboratory findings is characteristic of hairy cell leukemia (HCL)?</span></span></p>",
      "unique_key": "Q7732363",
      "question_audio": null,
      "question_video": null,
      "map_id": 20710,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Positive tartrate-resistant acid phosphatase (TRAP) stain</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The TRAP stain is a classic cytochemical test that is positive in hairy cells of HCL. The other options are not characteristic of HCL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Positive myeloperoxidase (MPO) stain:</strong> MPO is an enzyme found in myeloid cells (neutrophils, eosinophils, and monocytes) and is used to diagnose myeloid leukemias. It is not typically positive in HCL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Increased serum uric acid levels:</strong> While elevated uric acid levels can be seen in various hematologic malignancies due to increased cell turnover, it is not a specific finding for HCL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. BCR-ABL1 fusion gene:</strong> This genetic abnormality is the hallmark of chronic myeloid leukemia (CML) and is not associated with HCL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A positive TRAP stain is a useful diagnostic clue for hairy cell leukemia.</span></span></span></p>",
      "correct_choice_id": 82959,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20762,
      "choices": [
        {
          "id": 83011,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Psoriasis </span></span></span></p>"
        },
        {
          "id": 83012,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atopic dermatitis </span></span></span></p>"
        },
        {
          "id": 83013,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mycosis fungoides (MF) </span></span></span></p>"
        },
        {
          "id": 83014,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S&eacute;zary syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man presents with a persistent itchy, scaly rash on his trunk that has progressed over several months. Skin biopsy reveals epidermotropic lymphoid infiltrates with haloed lymphocytes. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q8899610",
      "question_audio": null,
      "question_video": null,
      "map_id": 20723,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Mycosis fungoides (MF)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The characteristic skin lesions, histopathological findings of epidermotropic lymphoid infiltrates with haloed lymphocytes, and progressive course are consistent with MF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Psoriasis:</span></strong><span style=\"font-size:12.0pt\"> Psoriasis can present with scaly plaques, but it usually has a well-demarcated border and lacks the characteristic epidermotropic lymphoid infiltrate with haloed lymphocytes seen in MF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>B. Atopic dermatitis:</strong> Atopic dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and scaly rashes. However, it does not typically present with epidermotropic lymphoid infiltrates or haloed lymphocytes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>D. S&eacute;zary syndrome:</strong> S&eacute;zary syndrome is an advanced form of cutaneous T-cell lymphoma (CTCL) characterized by erythroderma (widespread redness of the skin), circulating atypical T cells (S&eacute;zary cells), and generalized lymphadenopathy. While it can present with similar skin findings to MF, the widespread involvement and presence of S&eacute;zary cells in the blood distinguish it from early-stage MF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MF is the most common type of cutaneous T-cell lymphoma (CTCL) and presents with a variety of skin manifestations.</span></span></span></p>",
      "correct_choice_id": 83013,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20764,
      "choices": [
        {
          "id": 83019,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atopic dermatitis </span></span></span></p>"
        },
        {
          "id": 83020,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Psoriasis </span></span></span></p>"
        },
        {
          "id": 83021,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mycosis fungoides (MF) </span></span></span></p>"
        },
        {
          "id": 83022,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S&eacute;zary syndrome (SS)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man presents with generalized erythroderma (redness of the skin), intense pruritus, and lymphadenopathy. Peripheral blood smear reveals atypical lymphocytes with cerebriform nuclei. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q2571465",
      "question_audio": null,
      "question_video": null,
      "map_id": 20725,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) S&eacute;zary syndrome (SS)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of erythroderma, pruritus, lymphadenopathy, and atypical lymphocytes with cerebriform nuclei in the blood strongly suggests S&eacute;zary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Atopic dermatitis:</strong> While atopic dermatitis can cause itchy skin, it usually presents with localized patches of dry, scaly skin and does not typically cause erythroderma or lymphadenopathy. It also doesn&#39;t have the characteristic cerebriform nuclei seen in SS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Psoriasis:</strong> Psoriasis can also cause itchy, scaly skin, but the plaques are usually well-demarcated and silvery. It does not typically progress to erythroderma or involve lymph nodes. Again, the cerebriform nuclei are not a feature of psoriasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Mycosis fungoides (MF):</strong> MF is another type of CTCL and can share some skin features with SS. However, it usually progresses more slowly and doesn&#39;t always present with erythroderma. In the early stages of MF, the atypical lymphocytes are typically confined to the skin, not circulating in the blood.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SS is characterized by erythroderma, circulating S&eacute;zary cells, and lymphadenopathy.</span></span></span></p>",
      "correct_choice_id": 83022,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20774,
      "choices": [
        {
          "id": 83059,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple Myeloma </span></span></span></p>"
        },
        {
          "id": 83060,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Waldenstr&ouml;m macroglobulinemia </span></span></span></p>"
        },
        {
          "id": 83061,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monoclonal gammopathy of undetermined significance (MGUS) </span></span></span></p>"
        },
        {
          "id": 83062,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoldering multiple myeloma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old asymptomatic man undergoes routine blood tests, which reveal a serum M-protein level of 2.5 g/dL. Urine protein electrophoresis is negative. Bone marrow biopsy shows &lt;10% clonal plasma cells. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q3517962",
      "question_audio": null,
      "question_video": null,
      "map_id": 20735,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Monoclonal gammopathy of undetermined significance (MGUS)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MGUS is characterized by: * Serum M-protein &lt;3 g/dL * Bone marrow plasma cells &lt;10% * Absence of end-organ damage (CRAB criteria)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Multiple Myeloma:</strong> Multiple myeloma would present with a higher M-protein level, a greater percentage of plasma cells in the bone marrow, and evidence of end-organ damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Waldenstr&ouml;m macroglobulinemia:</strong> This is characterized by the overproduction of IgM antibodies, resulting in a high serum M-protein level. It also often presents with symptoms like hyperviscosity syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Smoldering multiple myeloma:</strong> This is a precursor to multiple myeloma with a higher M-protein level (&gt;3 g/dL) and/or bone marrow plasma cells (10-60%) but no end-organ damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MGUS is a common, premalignant condition that requires monitoring for progression to multiple myeloma.</span></span></span></p>",
      "correct_choice_id": 83061,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20777,
      "choices": [
        {
          "id": 83071,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1% </span></span></span></p>"
        },
        {
          "id": 83072,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10% </span></span></span></p>"
        },
        {
          "id": 83073,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">25% </span></span></span></p>"
        },
        {
          "id": 83074,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50%</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the approximate annual risk of progression of SMM to multiple myeloma?</span></span></p>",
      "unique_key": "Q2132547",
      "question_audio": null,
      "question_video": null,
      "map_id": 20737,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 10%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The average annual risk of progression of SMM to MM is approximately 10%. However, this risk can vary depending on individual risk factors and the presence of high-risk features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SMM has a significant risk of progression to MM, especially in the first few years after diagnosis.</span></span></span></p>",
      "correct_choice_id": 83072,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20779,
      "choices": [
        {
          "id": 83079,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monoclonal gammopathy of undetermined significance (MGUS) </span></span></span></p>"
        },
        {
          "id": 83080,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoldering multiple myeloma (SMM) </span></span></span></p>"
        },
        {
          "id": 83081,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple myeloma (MM) </span></span></span></p>"
        },
        {
          "id": 83082,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Waldenstr&ouml;m&#39;s macroglobulinemia (WM)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man presents with fatigue, bone pain, and elevated serum creatinine. Serum protein electrophoresis reveals an M-spike, and bone marrow biopsy shows 30% plasma cells. Skeletal survey reveals multiple lytic lesions. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q7216089",
      "question_audio": null,
      "question_video": null,
      "map_id": 20740,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Multiple myeloma (MM)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of bone pain, elevated creatinine (indicating renal insufficiency), lytic bone lesions, and &gt;10% clonal plasma cells in the bone marrow are consistent with multiple myeloma. This fulfills the CRAB criteria (hypercalcemia, Renal insufficiency, Anemia, Bone lesions) necessary for a diagnosis of MM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Monoclonal gammopathy of undetermined significance (MGUS):</strong> MGUS is a benign condition characterized by a small M-spike and low levels of plasma cells in the bone marrow (&lt;10%). Crucially, MGUS patients <em>do not</em> have end-organ damage (CRAB criteria).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Smoldering multiple myeloma (SMM):</strong> SMM is an intermediate stage between MGUS and multiple myeloma. While it has a higher risk of progression to myeloma, SMM patients typically lack the CRAB criteria that define multiple myeloma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Waldenstr&ouml;m&#39;s macroglobulinemia (WM):</strong> WM is a type of lymphoma characterized by the overproduction of IgM antibodies. While it can share some features with multiple myeloma (like an M-spike), the clinical presentation and bone marrow findings are different. WM typically does not cause lytic bone lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple myeloma is characterized by the presence of CRAB criteria, which distinguish it from MGUS and SMM.</span></span></span></p>",
      "correct_choice_id": 83081,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53042,
      "choices": [
        {
          "id": 211657,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Cilta-cel </span></span></span></p>"
        },
        {
          "id": 211658,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ide-cel </span></span></span></p>"
        },
        {
          "id": 211659,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Abecma </span></span></span></p>"
        },
        {
          "id": 211660,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Brexucabtagene autoleucel (Tecartus)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a type of chimeric antigen receptor (CAR) T-cell therapy approved for multiple myeloma?</span></span></p>",
      "unique_key": "Q4932339",
      "question_audio": null,
      "question_video": null,
      "map_id": 25170,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Brexucabtagene autoleucel (Tecartus)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Brexucabtagene autoleucel (Tecartus):</span></strong><span style=\"font-size:12.0pt\"> This CAR T-cell therapy targets CD19, a protein found on B cells. It is approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Cilta-cel (Carvykti):</strong> This CAR T-cell therapy targets the B-cell maturation antigen (BCMA) on myeloma cells. It is FDA-approved for adult patients with relapsed or refractory multiple myeloma after at least four prior lines of therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Ide-cel (Abecma):</strong> This is another BCMA-directed CAR T-cell therapy approved for adult patients with relapsed or refractory multiple myeloma after at least four prior lines of therapy. It was the first CAR T-cell therapy approved for myeloma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Abecma:</strong> This is the same therapy as Ide-cel.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CAR T-cell therapy is a promising new treatment option for relapsed/refractory multiple myeloma.</span></span></span></p>",
      "correct_choice_id": 211660,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53043,
      "choices": [
        {
          "id": 211661,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage I </span></span></span></p>"
        },
        {
          "id": 211662,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage II </span></span></span></p>"
        },
        {
          "id": 211663,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage III</span></span></span></p>"
        },
        {
          "id": 211664,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old patient with newly diagnosed multiple myeloma has a serum &beta;2-microglobulin (&beta;2m) level of 2.8 mg/L and serum albumin of 3.8 g/dL. Based on the ISS, what is this patient&#39;s stage?</span></span></p>",
      "unique_key": "Q3622838",
      "question_audio": null,
      "question_video": null,
      "map_id": 25171,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Stage I</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ISS categorizes multiple myeloma based on &beta;2m and albumin levels. This patient&#39;s &beta;2m is &lt;3.5 mg/L and albumin is &ge;3.5 g/dL, which corresponds to Stage I, associated with the best prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ISS stage is a significant prognostic indicator in multiple myeloma.</span></span></span></p>",
      "correct_choice_id": 211661,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53044,
      "choices": [
        {
          "id": 211665,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has standard-risk myeloma and a good prognosis. </span></span></span></p>"
        },
        {
          "id": 211666,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has high-risk myeloma and a poor prognosis. </span></span></span></p>"
        },
        {
          "id": 211667,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The t(14;16) translocation is not a significant prognostic factor in multiple myeloma. </span></span></span></p>"
        },
        {
          "id": 211668,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient requires immediate allogeneic stem cell transplantation.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with newly diagnosed multiple myeloma has a bone marrow biopsy revealing a t(14;16) translocation. Which of the following statements is true regarding this patient&#39;s prognosis?</span></span></p>",
      "unique_key": "Q9143031",
      "question_audio": null,
      "question_video": null,
      "map_id": 25172,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) The patient has high-risk myeloma and a poor prognosis.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The t(14;16) translocation is a high-risk cytogenetic abnormality in multiple myeloma, associated with aggressive disease and a shorter survival. High risk features: t(4;14), t(14;16), t(14;20), del17p13, +1q, LDH &ge; 2x, PCL</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Identifying high-risk cytogenetic features in multiple myeloma is crucial for risk stratification and treatment decisions.</span></span></span></p>",
      "correct_choice_id": 211666,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53045,
      "choices": [
        {
          "id": 211669,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple Myeloma (MM) </span></span></span></p>"
        },
        {
          "id": 211670,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Waldenstr&ouml;m Macroglobulinemia (WM) </span></span></span></p>"
        },
        {
          "id": 211671,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monoclonal Gammopathy of Undetermined Significance (MGUS) </span></span></span></p>"
        },
        {
          "id": 211672,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoldering Multiple Myeloma (SMM)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 75-year-old male presents with fatigue, weight loss, and blurred vision. Laboratory findings show elevated IgM levels and anemia. Bone marrow biopsy reveals lymphoid cells with plasmacytic differentiation. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q8381744",
      "question_audio": null,
      "question_video": null,
      "map_id": 25173,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Waldenstr&ouml;m Macroglobulinemia (WM)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s age, symptoms of hyperviscosity (blurred vision), elevated IgM, and bone marrow findings are highly suggestive of WM. MM is less likely due to the absence of lytic lesions and hypercalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Multiple Myeloma (MM):</strong> While MM can cause fatigue, weight loss, and anemia, it is less likely in this case due to the absence of lytic bone lesions (holes in the bones) and hypercalcemia (high calcium levels). MM also typically presents with elevated IgG or IgA, not IgM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Monoclonal Gammopathy of Undetermined Significance (MGUS):</span></strong><span style=\"font-size:12.0pt\"> MGUS is a benign condition where a small amount of monoclonal protein is present in the blood. It usually doesn&#39;t cause symptoms and wouldn&#39;t explain the patient&#39;s fatigue, weight loss, blurred vision, or anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Smoldering Multiple Myeloma (SMM):</strong> SMM is a precursor to multiple myeloma. While it shares some similarities with MM, it typically doesn&#39;t cause symptoms or organ damage. This patient&#39;s presentation with fatigue, weight loss, and blurred vision suggests a more active disease process than SMM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">WM often presents with hyperviscosity symptoms and bone marrow infiltration by lymphoplasmacytic cells.</span></span></span></p>",
      "correct_choice_id": 211670,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53046,
      "choices": [
        {
          "id": 211673,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cold agglutinins </span></span></span></p>"
        },
        {
          "id": 211674,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-MAG antibodies </span></span></span></p>"
        },
        {
          "id": 211675,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-cardiolipin antibodies </span></span></span></p>"
        },
        {
          "id": 211676,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-nuclear antibodies (ANA)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient diagnosed with WM presents with tingling and numbness in their extremities. Which of the following autoantibodies is most likely associated with this finding?</span></span></p>",
      "unique_key": "Q9623571",
      "question_audio": null,
      "question_video": null,
      "map_id": 25174,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Anti-MAG antibodies</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-MAG (myelin-associated glycoprotein) antibodies are associated with peripheral neuropathy in WM. Cold agglutinins can cause hemolytic anemia, while anti-cardiolipin antibodies and ANA are associated with autoimmune disorders like lupus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Cold agglutinins:</strong> These antibodies are associated with cold agglutinin disease (CAD), a type of autoimmune hemolytic anemia. While CAD can occur in WM, it typically presents with symptoms of anemia like fatigue and shortness of breath, not peripheral neuropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Anti-cardiolipin antibodies:</strong> These antibodies are associated with antiphospholipid syndrome, an autoimmune disorder that can cause blood clots. They are not typically associated with peripheral neuropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Anti-nuclear antibodies (ANA):</strong> ANAs are a group of antibodies that target components of the cell nucleus. They are commonly seen in systemic lupus erythematosus (SLE) and other autoimmune diseases, but not typically in WM-associated neuropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripheral neuropathy in WM is often associated with anti-MAG antibodies.</span></span></span></p>",
      "correct_choice_id": 211674,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53047,
      "choices": [
        {
          "id": 211677,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Autologous stem cell transplant (ASCT) </span></span></span></p>"
        },
        {
          "id": 211678,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allogeneic stem cell transplant (allo-SCT) from a matched related donor (MRD) </span></span></span></p>"
        },
        {
          "id": 211679,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allogeneic stem cell transplant (allo-SCT) from an unrelated donor (MUD) </span></span></span></p>"
        },
        {
          "id": 211680,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allogeneic stem cell transplant (allo-SCT) from umbilical cord blood (UCB)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with acute myeloid leukemia (AML) in first remission is being evaluated for stem cell transplantation. Which of the following types of transplant is most likely to offer a graft-versus-tumor (GVT) effect?</span></span></p>",
      "unique_key": "Q6071023",
      "question_audio": null,
      "question_video": null,
      "map_id": 25175,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Allogeneic stem cell transplant (allo-SCT) from a matched related donor (MRD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The graft-versus-tumor (GVT) effect is a unique feature of allo-SCT, where donor T cells recognize and eliminate residual leukemia cells. MRD allo-SCT is the most likely to offer this effect due to the closer immunological compatibility.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Autologous stem cell transplant (ASCT):</strong> In ASCT, the patient receives their own stem cells, which have been previously collected and stored. Since the immune system recognizes these cells as &quot;self,&quot; there is no GVT effect. ASCT is mainly used to allow for higher doses of chemotherapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Allogeneic stem cell transplant (allo-SCT) from an unrelated donor (MUD):</strong> While MUD allo-SCT can also elicit a GVT effect, the risk of graft-versus-host disease (GVHD) is higher than with MRD transplants due to increased immunological disparity. GVHD is a serious complication where the donor&#39;s immune cells attack the recipient&#39;s tissues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Allogeneic stem cell transplant (allo-SCT) from umbilical cord blood (UCB):</strong> UCB transplants also have a GVT effect, but they are often associated with slower engraftment and a higher risk of infection compared to MRD or MUD transplants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allo-SCT offers the advantage of a GVT effect, but also carries a higher risk of graft-versus-host disease (GVHD).</span></span></span></p>",
      "correct_choice_id": 211678,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53048,
      "choices": [
        {
          "id": 211681,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute graft-versus-host disease (GVHD) </span></span></span></p>"
        },
        {
          "id": 211682,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic graft-versus-host disease (GVHD) </span></span></span></p>"
        },
        {
          "id": 211683,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytomegalovirus (CMV) reactivation </span></span></span></p>"
        },
        {
          "id": 211684,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Engraftment syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient undergoing allogeneic stem cell transplantation (allo-SCT) develops a maculopapular rash, diarrhea, and elevated liver enzymes. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q4006378",
      "question_audio": null,
      "question_video": null,
      "map_id": 25176,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Acute graft-versus-host disease (GVHD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The triad of skin rash, diarrhea, and elevated liver enzymes is characteristic of acute GVHD, a common complication of allo-SCT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Chronic graft-versus-host disease (GVHD):</strong> While chronic GVHD can also affect the skin, gastrointestinal tract, and liver, it typically develops later after transplantation (months to years), and presents with different manifestations like skin thickening, dry eyes/mouth, and lung problems.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Cytomegalovirus (CMV) reactivation:</strong> CMV reactivation is a common complication of allo-SCT, but it typically presents with fever, fatigue, and less specific gastrointestinal symptoms. It doesn&#39;t usually cause the characteristic skin rash seen in GVHD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Engraftment syndrome:</strong> This is a non-infectious inflammatory syndrome that can occur shortly after transplant. It may present with fever, rash, and pulmonary edema, but it usually lacks the specific gastrointestinal symptoms of GVHD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute GVHD is a serious complication of allo-SCT and requires prompt diagnosis and treatment.</span></span></span></p>",
      "correct_choice_id": 211681,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}